addressing the role of parp inhibitors in different breast cancer settings
Published 6 years ago • 117 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
5:06
ovarian cancer: the role of parp inhibitors and beyond
-
3:46
case 4: parp inhibitors for treating brca triple-negative breast cancer
-
1:12
dr. joanne blum on the function of talazoparib in locally advanced and/or metastatic breast cancer
-
7:42
parp inhibitors in other subtypes of breast cancer
-
4:59
future role of parp inhibition in brca breast cancer
-
1:32:38
managed care implications of the expanding role of parp inhibitors in oncology
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
1:02:57
peri-operative therapy in urothelial carcinoma: uromigos live 2024
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
1:46
combination of veliparib and chemotherapy in brca-positive breast cancer
-
5:13
practical use of parp inhibitors in ovarian cancer
-
3:31
distinguishing between parp inhibitors in breast cancer
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
-
3:14
current and emerging roles of parp inhibition in ovarian cancer
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
1:17
the complexity of the parp inhibitor landscape in ovarian cancer
-
47:27
parp inhibitors: a breakthrough in cancer therapy?
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?